UCL Institute of Neurology
- IoN HOME
- About the Institute
- Study Here
- Research Departments
- Research Groups and Themes A-Z
- Department of Brain Repair & Rehabilitation
- Department of Clinical and Experimental Epilepsy
- Department of Clinical Neuroscience
- Department of Molecular Neuroscience
- Department of Neurodegenerative Disease
- Department of Neuroinflammation
- Sobell Department of Motor Neuroscience and Movement Disorders
- Wellcome Trust Centre for Neuroimaging
- Clinical Divisions
- Services & Library
- Vacancies and PhDs
- National Hospital for Neurology and Neurosurgery
- Contact Us
- Staff Intranet
- IoN Directory
UCL Institute of Neurology hosts inaugural Ada Lovelace Day event
Publication date: 23 October 2015
First human trial for innovative new drug in development to treat Huntington’s disease
Publication date: 19 October 2015
Patients in London are being dosed for the first time with an experimental drug for Huntington’s disease. This breakthrough could be one of the most important developments since the gene for Huntington’s disease was discovered in 1993. The trial of the revolutionary new ‘gene silencing’ treatment is being led by scientists at UCL’s Institute of Neurology. The first patients received doses of the drug at the Leonard Wolfson Experimental Neurology Centre at UCLH's National Hospital for Neurology and Neurosurgery.
UCL and UK supermarkets unite to beat dementia
Publication date: 5 October 2015
supermarkets Iceland, Asda, Morrisons and Waitrose have
today pledged funds from the new levy on single-use carrier bags to
construction of a new world class dementia research centre at UCL.
Possible evidence for human transmission of Alzheimer’s pathology
Publication date: 10 September 2015
Amyloid beta pathology in the grey matter and blood vessel walls characteristic of Alzheimer’s disease (AD) and the related cerebral amyloid angiopathy (CAA) is observed in the brains of deceased patients who acquired Creutzfeldt–Jakob disease (CJD) following treatment with prion-contaminated human growth hormone.
Compensation in Huntington’s disease
Publication date: 17 August 2015
A new measure has been developed which can explicitly characterise compensation in Huntington’s disease (HD) gene-carriers prior to clinical diagnosis. Publishing in EBioMedicine, the research team working on the study hope that identifying patterns of compensation in preclinical HD will not only improve understanding of neural mechanisms underlying HD pathology, but also provide potential targets that can be used in the testing of HD therapeutics.
Novel conceptual framework for tackling the global challenge of dementia
Publication date: 30 July 2015
Landmark 69-year study to provide window into dementia
Publication date: 14 July 2015
Study of brain changes 20 years before hereditary dementia symptoms start
Publication date: 13 July 2015
Researchers at UCL Institute of Neurology have been awarded a major grant to look at what happens in the brain of people who carry an abnormal gene linked to frontotemporal dementia (FTD) up to 20 years before symptoms start.
Natural genetic variation gives complete resistance in prion diseases
Publication date: 11 June 2015
Researchers at the Medical Research Council’s Prion Unit at the UCL Institute of Neurology have identified a naturally occurring variant of the human prion protein that produces resistance to prion diseases such as Creutzfeldt-Jakob disease (CJD). The findings, published in Nature, could give important insight into other human brain diseases that lead to dementia.
Behaviour changes common in early stage familial Alzheimer's
Publication date: 27 April 2015
Behavioural changes such as irritability, sleep changes and depression are common characteristics in the early stages of familial Alzheimer's disease, according to research published in Brain.
Imaging shows early brain changes in FTD patients
Publication date: 16 April 2015
Research using brain imaging has found changes in the brain can be identified in people with frontotemporal dementia (FTD) 5-10 years before symptoms appear.
New test measures deadly protein in Huntington’s disease patients’ spinal fluid
Publication date: 14 April 2015
A new test has been able to
measure for the first time the build-up of a harmful mutant protein in the
nervous system of patients during the progression of Huntington’s disease (HD).
Professor Nick Fox speaks about trial in early onset familial Alzheimer's disease at UCL
Publication date: 13 March 2015
Early onset Alzheimer's occurs in people under 65 and represents fewer than 5% of people with the condition. In a few hundred families worldwide scientists have pinpointed a few rare gene mutations which trigger the disease across many generations.
First major exhibition to explore BSE and its impact opens at Hayward Gallery
Publication date: 24 February 2015
UCL awarded £13.5 million to advance medical research facilities
Publication date: 23 October 2014
As part of the Clinical Research Infrastructure Initiative, UCL has been awarded £13.5 million for a number of projects to help advance clinical research.
Toxic proteins implicated in frontotemporal dementia and motor neurone disease
Publication date: 11 August 2014
Professor Tabrizi and Professor Price elected to Fellowship of the Academy of Medical Sciences.
Publication date: 12 May 2014
Professor Sarah Tabrizi (Department of Neurodegenerative Diseases, UCL Institute of Neurology and
Honorary Consultant Neurologist at the National Hospital of Neurology and
Neurosurgery) and Professor Cathy Price (Wellcome Trust Centre for Neuroimaging, UCL Institute of Neurology) have been recognised for their contribution to the advancement of medical science by election to the Fellowship of the Academy of Medical Sciences.
Population Screening for vCJD Using a Novel Blood Test
Publication date: 7 March 2014
There are real concerns
over the number of people in the UK that, although well, maybe infected with Variant Creutzfeldt-Jakob Disease (vCJD),
the human form of mad cow disease.
Chief Medical Officer appoints Professor Rossor as NIHR National Director for Dementia Research
Publication date: 4 March 2014
Lowering levels of toxic protein reverses abnormalities in cells from patients with Huntington's disease
Publication date: 24 January 2014
UCL scientists, led by Professor Sarah Tabrizi at the UCL Institute of Neurology, in collaboration with colleagues at the University of Massachusetts Medical School, have shown for the first time that switching off the mutant protein that causes the fatal brain disorder Huntington’s disease can reverse abnormalities in living cells taken from patients with the disease.
UCL takes the lead with £8.5m funding for dementia research
Publication date: 11 December 2013
UCL has been awarded more than £8.5 million by the Economic and Social Research Council (ESRC) and the National Institute for Health Research (NIHR) to help tackle the challenges associated with dementia.
Secretary of State visits leading dementia research projects
Publication date: 11 December 2013
The Prime Minister today called for a global effort to tackle one of the greatest challenges of our time: dementia. UCL scientists, working with clinicians at the university's partner hospitals, are at the heart of the battle to treat the condition.
New £20m centre pioneers first-in-man trials for neurodegenerative diseases
Publication date: 15 November 2013
A specialist £20 million research centre, funded by the Wolfson Foundation and dedicated to carrying out first-in-human studies, opens in London today. Researchers at the Leonard Wolfson Experimental Neurology Centre (LWENC) will investigate exciting new therapies for neurodegenerative diseases such as Alzheimer’s and Parkinson’s.
RNA build-up linked to dementia and motor neuron disease
Publication date: 4 November 2013
A new toxic entity associated with genetically inherited forms of dementia and motor neuron disease has been identified by scientists at the UCL Institute of Neurology. The toxin is the result of a genetic mutation that leads to the production of RNA molecules which could be responsible for the diseases. The findings are published in the journal Acta Neuropathologica.
Researchers estimate one in 2,000 people in the UK carry variant CJD proteins
Publication date: 16 October 2013
A study led by Sebastian Brandner at the Department of Neurodegenerative disease, UCL Institute of Neurology, in collaboration with the AHVLA in Weybridge and Public Health England shows all ages and genotypes to be affected.